文献速递冠心病血脂与心血管预防

糖尿病合并冠心病患者中两亲霉素洗脱支架与佐他莫司洗脱支架对比:SUGAR随机试验延长随访

Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial.
PubMed 文献 · Heart · 2025-11-25

SUGAR试验在1175例糖尿病合并冠心病患者中比较两亲霉素洗脱支架(AES)与Onyx佐他莫司洗脱支架(O-ZES)的疗效。2年靶病变失败(TLF)率AES组10.4%对O-ZES组12.1%(HR 0.84,95%CI 0.60-1.19,P=0.331),3年TLF率11.4%对14.9%(HR 0.77,95%CI 0.56-1.06,P=0.106),两组长期疗效相当。

要点

  • 糖尿病合并冠心病患者PCI后,AES与O-ZES的2年和3年TLF率均无显著差异。
  • 1至3年landmark分析显示两组TLF率无显著差异(HR 1.07,95%CI 0.62-1.87,P=0.801)。
  • 两组全因死亡、支架血栓和主要不良心脏事件等次要终点均无显著差异。

核心结论

  • 在糖尿病合并冠心病行PCI的患者中,AES与O-ZES在预防靶病变失败方面提供相当的长期疗效,支持任一种支架类型的选用。

研究设计与样本

  • SUGAR试验(NCT03321032)为随机、评估者盲法、1:1分配的多中心研究,纳入1175例糖尿病患者,覆盖23个中心,比较AES(Cre8EVO)与O-ZES(Resolute Onyx),采用Cox比例风险模型评估主要终点。

主要发现

  • 2年TLF在AES组发生60例(10.4%),O-ZES组71例(12.1%),HR 0.84(95%CI 0.60-1.19),P=0.331。
  • 3年TLF在AES组发生66例(11.4%),O-ZES组87例(14.9%),HR 0.77(95%CI 0.56-1.06),P=0.106。
  • 1至3年landmark分析TLF率无显著差异,HR 1.07(95%CI 0.62-1.87),P=0.801。
  • 主要终点各单项组分及次要终点(全因死亡、支架血栓、主要不良心脏事件)在两组间均无显著差异。

临床怎么用

  • 糖尿病合并冠心病患者行PCI时,AES与O-ZES均可作为选择,长期TLF风险相当。
  • 需关注糖尿病患者PCI后的晚期事件风险,现有证据支持任一种支架类型,但仍需更长期研究优化预后。

局限性

  • 原文摘要未明确报告研究的局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with diabetes mellitus (DM) have an elevated risk of late events after percutaneous coronary intervention (PCI). The Second-generation Drug-eluting Stents in Diabetes (SUGAR) trial (NCT03321032) compared amphilimus-eluting stents (AESs) and onyx-zotarolimus-eluting stents (O-ZESs) in this population. OBJECTIVES: To report the co-primary endpoint comparing target lesion failure (TLF) between AES and O-ZES at 2 years and the extended follow-up at 3 years. METHODS: The SUGAR trial enrolled 1175 patients with DM across 23 centres in a randomised (1:1 AES (Cre8EVO) or O-ZES (Resolute Onyx)) assessor-blinded design. The primary endpoint, assessed with a Cox proportional hazards model, was TLF (a composite of cardiac death, target vessel myocardial infarction or ischaemia-driven target lesion revascularisation). Secondary endpoints included all-cause mortality, stent thrombosis and major adverse cardiac events. RESULTS: At 2 years, TLF occurred in 60 (10.4%) patients in the AES group and 71 (12.1%) in the O-ZES group; HR 0.84 (95% CI 0.60 to 1.19), p=0.331. At 3 years, TLF occurred in 66 (11.4%) of the AES group compared with 87 (14.9%) of the O-ZES group (HR 0.77; 95% CI 0.56 to 1.06; p=0.106). Landmark analysis revealed no significant differences in TLF rates between 1 and 3 years (HR 1.07; 95% CI 0.62 to 1.87; p=0.801). Rates of individual components of the primary endpoint were comparable between groups. No significant differences were observed in secondary endpoints. CONCLUSIONS: The SUGAR trial demonstrates that AES and O-ZES provide comparable long-term efficacy in preventing TLF in patients with DM undergoing PCI. These findings support the use of either stent type and highlight the importance of further long-term studies to optimise outcomes. TRIAL REGISTRATION NUMBER: NCT03321032.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Salinas P, Romaguera R, Gómez-Lara J, et al. Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial. Heart. 2025. PMID: 40562528. doi:10.1136/heartjnl-2025-325773

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。